百时美施贵宝(BMY.US)重磅抗精神病药物获批带动股价盘前大涨

智通财经网09-27

智通财经APP获悉，美国食品和药物管理局(FDA)周四批准了由美国医药巨头百时美施贵宝公司(BMY.US)开发的Cobenfy(xanomeline以及trospium chloride)，作为治疗精神分裂症成人患者的最新疗法。受益于这一利好消息，周五百时美施贵宝股价在美股盘前交易中一度大涨约 6%，今年以来该公司股价可谓长期低迷。该公司宣布计划在10月底推出 Cobenfy，每月定价 ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2470708827?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20240927/20240927205757_80323.png?x-oss-process=image/format,jpg/quality,Q_80","is_english":false,"pubTime":"2024-09-27 20:55","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2470708827","market":"sh","top_or_hot":-1,"title":"百时美施贵宝(BMY.US)重磅抗精神病药物获批 带动股价盘前大涨","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，美国食品和药物管理局(FDA)周四批准了由美国医药巨头百时美施贵宝公司(BMY.US)开发的Cobenfy(xanomeline以及trospium  chloride)，作为治疗精神分裂症成人患者的最新疗法。受益于这一利好消息，周五百时美施贵宝股价在美股盘前交易中一度大涨约  6%，今年以来该公司股价可谓长期低迷。该公司宣布计划在10月底推出 Cobenfy，每月定价 ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1188456.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百时美施贵宝(BMY.US)重磅抗精神病药物获批 带动股价盘前大涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百时美施贵宝(BMY.US)重磅抗精神病药物获批 带动股价盘前大涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-27 20:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1188456.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，美国食品和药物管理局(FDA)周四批准了由美国医药巨头百时美施贵宝公司(BMY.US)开发的Cobenfy(xanomeline以及trospium  chloride)，作为治疗精神分裂症成人患者的最新疗法。受益于这一利好消息，周五百时美施贵宝股价在美股盘前交易中一度大涨约  6%，今年以来该公司股价可谓长期低迷。该公司宣布计划在10月底推出 Cobenfy，每月定价 ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1188456.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0868494617.USD","symbol_name":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1188456.html","article_id":"2470708827","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20240927/20240927205757_80323.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470708827","pubTimestamp":1727441738,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"FDA周四批准了由美国医药巨头百时美施贵宝公司开发的Cobenfy(xanomeline以及trospium chloride)，作为治疗精神分裂症成人患者的最新疗法。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BMY":"施贵宝","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","BK4585":"ETF&股票定投概念","BK4007":"制药","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0237698245.USD":"富达环球地产基金A","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4559":"巴菲特持仓","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4588":"碎股","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4581":"高盛持仓","LU0882574055.USD":"富达全球健康医疗A ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc"},"translate_title":"Bristol-Myers Squibb (BMY.US) 's blockbuster antipsychotic drug approved, driving stock prices to surge before the market","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":1},"content_text":"智通财经APP获悉，美国食品和药物管理局(FDA)周四批准了由美国医药巨头百时美施贵宝公司(BMY.US)开发的Cobenfy(xanomeline以及trospium  chloride)，作为治疗精神分裂症成人患者的最新疗法。受益于这一利好消息，周五百时美施贵宝股价在美股盘前交易中一度大涨约  6%，今年以来该公司股价可谓长期低迷。该公司宣布计划在10月底推出 Cobenfy，每月定价 1850 美元，每年定价大约 22500 美元。据了解，该创新药物以前被称为KarXT，在3月份以140亿美元收购Karuna  Therapeutics后，被添加到这家美国医药巨头(BMY)的管道产品中。据了解，总部位于马萨诸塞州波士顿的PureTech  Health(PRTC.US)是KarXT的原始发明者，周五表示，在获得FDA批准后，它将获得高达2900万美元的两笔里程碑付款，作为其与创始实体Karuna，以及生物科技公司Royalty  Pharma合作协议的一部分。因此受益于这一消息，PureTech Health股价在美股盘前也有所上涨，涨幅一度高达5%。当百时美施贵宝于12月与Karuna  签署收购协议之时，该抗精神病的新型药物正在接受美国食品和药物管理局(FDA)的审查，目标行动日期为2024年9月26日。与多巴胺受体靶向精神分裂症疗法不同，目前的护理标准Cobenfy是第一个获得FDA批准的针对胆碱能受体的抗精神病药。因为它不通过抑制多巴胺受体来起效，Cobenfy  避免了许多与现有抗精神病药物相关的副作用，尤其是运动障碍(如静坐不能、震颤等)和代谢综合征(如体重增加、血糖升高)。这使得它对于那些难以忍受传统药物副作用的患者来说是一种更安全的选择。Cobenfy  的创新之处在于，它作用于胆碱能受体，特别是M1型和M4型胆碱能受体，而非直接作用于多巴胺系统。通过这种机制，Cobenfy有可能改善认知功能和负性症状。胆碱能系统与认知功能和情绪调节密切相关。通过靶向胆碱能受体，Cobenfy可能在改善患者的认知功能和负性症状方面展现出优势，而这些是目前的多巴胺阻断药物难以有效处理的领域。这对于长期治疗精神分裂症患者，尤其是那些出现认知障碍和社交功能减退的患者，可能具有重要意义。“这种药物是几十年来精神分裂症治疗的首个新方法，”美国食品和药物管理局药物评估和研究中心神经科学办公室精神病学部主任蒂芙尼·法尔奇奥尼表示。她补充表示：“这一批准为精神分裂症患者们除了以前长期服用的抗精神病药物之外，提供了一种全新的选择。”","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470708827"}

百时美施贵宝(BMY.US)重磅抗精神病药物获批 带动股价盘前大涨

精彩评论

百时美施贵宝(BMY.US)重磅抗精神病药物获批带动股价盘前大涨